Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis.

Daniel V Araujo; J Connor Wells; Aaron R Hansen; Nazli Dizman; Sumanta K Pal; Benoit Beuselinck; Frede Donskov; Chun L Gan; Flora Yan; Ben Tran; Christian K Kollmannsberger; Guillermo de Velasco; Takeshi Yuasa; M Neil Reaume; D Scott Ernst; Thomas Powles; Georg A Bjarnason; Toni K Choueiri; Daniel YC Heng; Shaan Dudani

Journal article

Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis.

Daniel V Araujo, J Connor Wells, Aaron R Hansen, Nazli Dizman, Sumanta K Pal, Benoit Beuselinck, Frede Donskov, Chun L Gan, Flora Yan, Ben Tran, Christian K Kollmannsberger, Guillermo de Velasco, Takeshi Yuasa, M Neil Reaume, D Scott Ernst, Thomas Powles, Georg A Bjarnason, Toni K Choueiri, Daniel YC Heng, Shaan Dudani

Journal of Geriatric Oncology | Published : 2021

DOI: 10.1016/j.jgo.2021.02.022

Abstract

OBJECTIVE: Older adults with metastatic renal cell carcinoma(mRCC) are underrepresented in immune-checkpoint inhibitor(ICI) registration trials. Here we compare the efficacy of ICI treatments in older vs. younger adults with mRCC. METHODS: Using the International mRCC Database Consortium(IMDC), patients treated with a PD(L)-1 based ICI were identified. Older adult was defined as ≥70-years at the time of treatment. Descriptive statistics were summarized in means, medians, and proportions. Effectiveness endpoints included overall survival (OS), time-to-treatment failure(TTF), time-to-next treatment(TNT), and overall response rate(ORR). Hazards ratios were adjusted(aHR) for IMDC risk factors, h..

View full abstract